Literature DB >> 26289313

Immunotherapy: Engineering a sTrategy for multiple myeloma.

Mina Razzak1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26289313     DOI: 10.1038/nrc4006

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  1 in total

1.  NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.

Authors:  Aaron P Rapoport; Edward A Stadtmauer; Gwendolyn K Binder-Scholl; Olga Goloubeva; Dan T Vogl; Simon F Lacey; Ashraf Z Badros; Alfred Garfall; Brendan Weiss; Jeffrey Finklestein; Irina Kulikovskaya; Sanjoy K Sinha; Shari Kronsberg; Minnal Gupta; Sarah Bond; Luca Melchiori; Joanna E Brewer; Alan D Bennett; Andrew B Gerry; Nicholas J Pumphrey; Daniel Williams; Helen K Tayton-Martin; Lilliam Ribeiro; Tom Holdich; Saul Yanovich; Nancy Hardy; Jean Yared; Naseem Kerr; Sunita Philip; Sandra Westphal; Don L Siegel; Bruce L Levine; Bent K Jakobsen; Michael Kalos; Carl H June
Journal:  Nat Med       Date:  2015-07-20       Impact factor: 53.440

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.